Efforts to localize human genes to specific chromosomes and then to identify these genes and their role in specific diseases are increasing. These developments will expand the repertoire of genetic tests that are claimed to be predictive of future disease in the person being tested (prosymptomatic tests) or in future offspring of those being tested US for PKU because benefit occurs only when this special diet is introduced before the disease becomes apparent clinically (1).
When no efficacious interventions for a genetic condition are available, predictive genetic tests provide people who are at risk of having children with that condition options they would otherwise not have. Such testing before pregnancy provides women or couples at risk the option of avoiding conception of an affected child. Such testing early in pregnancy provides the options of termination of pregnancy or preparing for the birth of an affected child.
Uncertainties about whether a condition will appear, how severe it will be, and whether interventions will be efficacious complicate decisions about the use of predictive genetic tests. For instance, the survival of children with cystic fibrosis (CF) is highly variable, despite improved therapy over the past decade (2 
ClassificatIon of Genetic Disease
Let me turn now from types of genetic tests to a classification of genetic diseases. First are the singlegene disorders such as PKU, CF, sickle cell anemia, and hemophilia. The list is very large and will grow larger as we identify genes through the Human Genome Proj- Until very recently, HD was detectable in families only through linkage studies; now the mutation has been identified (6). One concern of Gusella and his colleagues after they localized the HD gene by linkage studies to chromosome 4 was whether HD could be caused by genes at other loci (7) . Consequently, they contacted several other investigators who had accessto HI) families and, through a collaboration, finally established the extremely high sensitivity of testing for linkage to their markers on chromosome 4. In the meantime, some clinicians not in their collaborative study were eager to use this test and asked Gusella for the probes. Gusella 
refused. The clinicians objected in a public letter (8):
If Wassermann had published his test for syphilis, which was far from reliable, in a way which delayed its application, neurosyphus might now be more common than Huntington's chorea. This infectious disease involves far moredifficult problems in handling patients and their families; many individuals must have been distressedby investigationsbasedon error, andthere were probably a few suicides. But the disease is now rare in Northern Europe. In no field of effective medicine can techniques be applied without casualties. This is a chilling statement. If one is unwilling to risk a few suicides, and suicide has been a problem in HD, the approach used by Gusella to establish sensitivity of his linkage tests was necessary.
A secondexample relating to genetic heterogeneity is CF. In the first series of papers reporting the discovery of the gene, one mutation was found to account for 68% of CF carriers (9). Do we consider thislevel of sensitivity sufficient to begin to test for carriers in the general population? Although the survival of those with CF is improving, and gene therapy holds hope for a cure, it is a debffitating disease for many. Carrier screening before or early in pregnancy provides the options of pronatal diagnosis and abortion. What are the implications of carrier testing of couples when the sensitivity of the test is 70%? If both parents are found to carry one of the detectable mutations they have a one in four chance of having a child with CF with each pregnancy. Because both parents' mutations can be detected, so can the CF alleles that the fetus inherits. Thus prenatal diagnosis will be able to predict with certainty whether the fetus The problem of predictive value is much more serious for multifactorial disorders. Because other factors are also involved in the causation, one must be very conservative in making estimates of how frequently a positive test result for the genetic predisposing factor will predict future disease.
A recent report described an association between a specific allele for human leukocyte antigen (HLA) and chronic berylliosis (16). Companies in which workers handle beryllium might want to screen job applicants for the HLA allele and refuse to hire those who have it. However, not all of the workers who had chronic berylliosis had this particular HLA allele. Moreover, many workers exposed to beryllium and who were free of the disease also had the allele.
Another example involves the association of Alzheimer disease with a specific apoE4 allele at the apolipoprotein (ape) E gene locus on chromosome 19 . The data in Table 1 are recalculated from another study (17) , which was limited to -40 families in which Alzheimer disease occurred after age 60. Ages of the family members with Alzheimer were 60 to 91 years; those without it were 66 to 94. Thus, many of the people in the unaffected group would already have shown signs of the Of all those people yielding positive reactions, only about onehalf were actually syphilitic, but this 'validation', so to speak, of the test, this characteriiaPon of its inadequacies, was only performed decades after large-scale public health campaigns (including laws governing premarital eTaminJltions) had brought thousands of people under treatment ... These four or five decades, during which thousands of patients who did not have syphilis were subjected to the shame and dangers of antisyphilitic therapy, are not from the era of bleedings and leachings, but from the modern era of interventionist technology.
Safety and Efficacy
Genetic screening is not an end in itself. The intervention that follows can range from prenatal diagnosis after identification of a high-risk pregnancy by screening, and abortion of those fetuses found to be affected, to the institution of a drug or special diet to prevent the appearance of symptoms after presymptomatic Once again, syphilis proves instructive. In a Scandinavian study, people with primary syphilis defined cmkelly who were not treated with arsenicals were traced over their lifetime. Only about 20% of them went on to develop tertiary syphilis (19) . So, even when the diagnosis has been established, the natural history of the disorder cannot be predicted clearly. I will return to this point when we consider the efficacy of interventions.
Assume that scientists have identified the BRCA1 gene and a few mutations at that locus that are strongly associated with breast cancer in high-risk families. It then would become possible to develop a test to screen women in the general population for those mutations. Although 80% of women in high-risk families who have those alleles are likely to develop breast cancer over their lifetimes, it is by no means certain that the same mutations-or other mutations at the same locus-will indicate such a poor prognosis in the general population. Given the likelihood that somatic mutations are needed before breast cancer occurs in those who inherit a BRCA1 mutation (4), it is quite possible that the presence of other genetic or environmental we wouldn't be able to tell how many would go on to develop cancer. We might think that the number of women sotreated who then did not develop cancer was evidence that surgery was a "cure," when, in fact, many of the women undertaking it might not have developed cancer anyway.
One way around this dilemma is to enroll women into combined pilot screening studies and randomized controlled trials in which it is explained to them that we don't know the risk of cancer when the screening test result is positive and that we don't know the efficacy of bilateral mastectomy (or whatever intervention is on trial) in preventing cancer. Ideally, women with positive screening test results would be randomized to prophylactic surgery or to a control group. The rate of breast cancer in the positive control group would tell us the people who may not have thought about having them; it will often be the physician or health provider who introduces them. They are not foremost in the thoughts or on the tips of the tongues of most people obtaining healthcare today. Unfortunately, few physicians are willing or able to spend time to inform people and obtain truly informed consent.
In conclusion, the localization and identification of genes is, today, one of the most rapidly growing areas of research, as evidenced by increasing funding for the Human Genome Project. As associations between newly discovered genes and specific diseases are made, the temptation to screen people for the presence of diseaserelated alleles will be great. The issues discussed here should sound a cautionary note about the use of genetic tests for predictive purposes. If the public is to be protected, stringent application of existing clinical laboratory regulations to genetic testing will be needed as well as new policies to assure long-term validation of test results and efficacy of interventions.
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